dc.creator | Sagris D., Ntaios G., Georgiopoulos G., Pateras K., Milionis H. | en |
dc.date.accessioned | 2023-01-31T09:52:42Z | |
dc.date.available | 2023-01-31T09:52:42Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.ejim.2020.11.021 | |
dc.identifier.issn | 09536205 | |
dc.identifier.uri | http://hdl.handle.net/11615/78666 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | European Journal of Internal Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099717070&doi=10.1016%2fj.ejim.2020.11.021&partnerID=40&md5=956006ad0a5ae45370fb06af4d747c46 | |
dc.subject | low density lipoprotein cholesterol | en |
dc.subject | placebo | en |
dc.subject | proprotein convertase 9 | en |
dc.subject | serine proteinase inhibitor | en |
dc.subject | hypocholesterolemic agent | en |
dc.subject | proprotein convertase 9 | en |
dc.subject | subtilisin | en |
dc.subject | acute coronary syndrome | en |
dc.subject | brain hemorrhage | en |
dc.subject | brain ischemia | en |
dc.subject | follow up | en |
dc.subject | human | en |
dc.subject | Letter | en |
dc.subject | meta analysis | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | risk reduction | en |
dc.subject | systematic review | en |
dc.subject | cardiovascular disease | en |
dc.subject | cerebrovascular accident | en |
dc.subject | Anticholesteremic Agents | en |
dc.subject | Cardiovascular Diseases | en |
dc.subject | Humans | en |
dc.subject | Proprotein Convertase 9 | en |
dc.subject | Stroke | en |
dc.subject | Subtilisins | en |
dc.subject | Elsevier B.V. | en |
dc.title | Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis | en |
dc.type | other | en |